Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from 10 mg/ml to 20 mg/ml treprostinil in pulmonary arterial hypertension
2021-004002-21Phase 2Completed
- Sponsor
- AOP Health
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by AOP Health. Primary endpoint: Average concentration of treprostinil at steady state (Cavgss). Started Sep 2021; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2021-004002-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004002-21.